eFFECTOR Therapeutics (NASDAQ:EFTR – Get Free Report) will likely be releasing its resultson Wednesday, August 12th. Analysts expect eFFECTOR Therapeutics to announce earnings of ($6.3960) per share and revenue of $0.10 million for the quarter.
eFFECTOR Therapeutics Price Performance
NASDAQ:EFTR opened at $0.00 on Wednesday. eFFECTOR Therapeutics has a 12-month low of $0.00 and a 12-month high of $0.02. The stock has a market cap of $940.80, a P/E ratio of -0.00 and a beta of 2.38.
eFFECTOR Therapeutics Company Profile
eFFECTOR Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of precision medicines that modulate protein synthesis to treat cancer. The company’s research leverages a proprietary translational control platform designed to identify small‐molecule inhibitors of key regulatory proteins involved in mRNA translation. By targeting elements of the eukaryotic initiation factor pathway, eFFECTOR aims to impair the ability of tumor cells to produce proteins necessary for growth and survival.
The company’s lead clinical candidate, tomivosertib (eFT508), is a selective MNK1/2 inhibitor being evaluated in Phase 2 trials across multiple solid tumor indications.
Featured Stories
- Five stocks we like better than eFFECTOR Therapeutics
- Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
- System Upgrade: First Internet Bancorp Options Surge
Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
